Zepbound 12.5 MG/0.5 ML pen 0.5ML
Ended Awarded
- Contract number
- SPE2DB26FWRN8
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,352
Award facts
- Contract value 100% obligated
- $14,351.78 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $14,351.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Zepbound (tirzepatide) 12.5 mg/0.5 mL in pen form. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract is non-set-aside and was competitively awarded, with a place of performance in Conshohocken, Pennsylvania, and an ultimate completion date of October 28, 2025. Zepbound is a GLP-1 receptor agonist used for weight management and is part of the broader pharmaceutical and medical supply portfolio that AmerisourceBergen delivers to support military healthcare systems and federal medical procurement needs.
As a child delivery order under the SPE2DX prime IDC, this award reflects AmerisourceBergen's established role as a critical pharmaceutical distributor for the Department of Defense's medical supply chain. The company's contract portfolio with DLA demonstrates extensive experience fulfilling federal procurement requirements across multiple therapeutic domains, including specialty medications, vaccines, and medical devices. The short completion timeframe indicates a high-priority supply need for the Defense Health Agency and other military healthcare customers. DLA Troop Support is planning to establish next-generation Pharmaceutical Prime Vendor Global Program Generation V contracts with potential multiple award structures, positioning AmerisourceBergen among key strategic vendors for continued military pharmaceutical support.
Quick answers
Who was awarded contract SPE2DB26FWRN8?
SPE2DB26FWRN8 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DB26FWRN8 worth?
The government has obligated $14,352 on SPE2DB26FWRN8.
Is contract SPE2DB26FWRN8 an order under another contract?
Yes. SPE2DB26FWRN8 is a delivery order under SPE2DB24D2018, an indefinite delivery contract.
Was contract SPE2DB26FWRN8 competed?
The extent of competition for SPE2DB26FWRN8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award